Lexicon Pharmaceuticals (LXRX) News Today $0.83 +0.02 (+2.77%) (As of 10:02 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Lexicon Pharmaceuticals Appoints Ivan Cheung to BoardNovember 20 at 11:15 PM | markets.businessinsider.comIvan H. Cheung Elected to Board of Directors of Lexicon Pharmaceuticals, Inc.November 20 at 6:05 PM | quiverquant.comLexicon Appoints Ivan H. Cheung to Board of DirectorsNovember 20 at 4:20 PM | globenewswire.comLexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market ActivityNovember 20 at 4:09 PM | gurufocus.comQ4 Earnings Estimate for LXRX Issued By Leerink PartnrsNovember 19 at 3:13 AM | americanbankingnews.comLexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past weekNovember 18 at 8:05 PM | finance.yahoo.comLeerink Partnrs Has Bullish Outlook for LXRX Q4 EarningsLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Stock analysts at Leerink Partnrs raised their Q4 2024 EPS estimates for shares of Lexicon Pharmaceuticals in a research report issued to clients and investors on Thursday, November 14th. Leerink Partnrs analyst R. Ruiz now expects thatNovember 18 at 3:05 AM | marketbeat.comWhat is HC Wainwright's Estimate for LXRX FY2024 Earnings?November 17, 2024 | americanbankingnews.comWhat is HC Wainwright's Forecast for LXRX FY2024 Earnings?Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Stock analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Lexicon Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst J. Pantginis now foreNovember 15, 2024 | marketbeat.comLexicon announces data from four stories of sotagliflozin to be deliveredNovember 14, 2024 | markets.businessinsider.comLexicon Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comDemystifying Lexicon Pharmaceuticals: Insights From 10 Analyst ReviewsNovember 13, 2024 | benzinga.comLexicon Pharmaceuticals: Strategic Advancements and Financial Stability Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comLexicon Pharmaceuticals (LXRX) Gets a Buy from Piper SandlerNovember 13, 2024 | markets.businessinsider.comLexicon Pharmaceuticals' (LXRX) "Hold" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Wednesday.November 13, 2024 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $6.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Wednesday.November 13, 2024 | marketbeat.comLexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...November 13, 2024 | finance.yahoo.comLexicon Pharmaceuticals options imply 14.8% move in share price post-earningsNovember 13, 2024 | markets.businessinsider.comLexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comLexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comPreview: Lexicon Pharmaceuticals's EarningsNovember 11, 2024 | benzinga.comLexicon Pharmaceuticals Q3 2024 Earnings PreviewNovember 11, 2024 | msn.comLexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look ForNovember 11, 2024 | finance.yahoo.comLexicon Pharmaceuticals (LXRX) Scheduled to Post Earnings on TuesdayLexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports.November 6, 2024 | marketbeat.comLexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare ConferenceNovember 6, 2024 | globenewswire.comPublished Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney DiseaseNovember 5, 2024 | globenewswire.comLexicon Pharmaceuticals' (LXRX) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $6.00 target price on shares of Lexicon Pharmaceuticals in a research note on Tuesday.November 5, 2024 | marketbeat.comLexicon to present data from two studies related to LX9851November 4, 2024 | markets.businessinsider.comLexicon price target lowered to $6 from $10 at H.C. WainwrightNovember 2, 2024 | markets.businessinsider.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Quotes, Forecast and News SummaryNovember 2, 2024 | benzinga.comFDA Panel Rejects Lexicon's Zynquista For Type 1 DiabetesNovember 1, 2024 | benzinga.comLexicon Pharma in selloff as FDA AdCom rebukes diabetes drug (update)November 1, 2024 | msn.comLexicon Pharmaceuticals Halted All Day as FDA Panel Reviews ZynquistaNovember 1, 2024 | marketwatch.comOptimistic Buy Rating for Lexicon Pharmaceuticals Due to Positive Outlook on Sotagliflozin’s FDA ReviewNovember 1, 2024 | markets.businessinsider.comLexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista -- UpdateOctober 31, 2024 | marketwatch.comFDA Panel Votes Against Lexicon's NDA For Zynquista In Type 1 Diabetes And Chronic Kidney DiseaseOctober 31, 2024 | markets.businessinsider.comFDA panel votes 11-3 that Lexicon’s Zynquista benefits do not outweigh risksOctober 31, 2024 | markets.businessinsider.comLexicon's sotagliflozin fails to win support of FDA AdComm for diabetes (update)October 31, 2024 | msn.comLexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney DiseaseOctober 31, 2024 | globenewswire.comFDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetesOctober 31, 2024 | reuters.comLexicon Pharmaceuticals' (LXRX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Lexicon Pharmaceuticals in a report on Wednesday.October 30, 2024 | marketbeat.comNeedham & Company LLC Reaffirms "Hold" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)Needham & Company LLC reissued a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday.October 30, 2024 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 9.7% - Here's WhyLexicon Pharmaceuticals (NASDAQ:LXRX) Trading 9.7% Higher - Here's WhyOctober 29, 2024 | marketbeat.comFDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meetingOctober 27, 2024 | markets.businessinsider.comLexicon announces new analysis of Phase 3 SCORED trialOctober 24, 2024 | markets.businessinsider.comNew Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024October 23, 2024 | markets.businessinsider.comLexicon Pharmaceuticals (NASDAQ:LXRX) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Lexicon Pharmaceuticals in a research report on Wednesday.October 23, 2024 | marketbeat.comLexicon’s LX9211 progressing ahead of schedule, says H.C. WainwrightOctober 22, 2024 | markets.businessinsider.comLexicon completes screening in Phase 2B progress study of LX9211October 22, 2024 | markets.businessinsider.comLexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)October 22, 2024 | finance.yahoo.com Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. LXRX Media Mentions By Week LXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRX News Sentiment▼0.250.46▲Average Medical News Sentiment LXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRX Articles This Week▼163▲LXRX Articles Average Week Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IRWD News EBS News RIGL News SGMO News XOMA News CDXS News VNDA News VSTM News ACHV News RGLS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
